Cipla has settled its patent litigation with Celgene over the blockbuster cancer drug Revlimid. Celgene Corporation, a subsidiary of Bristol Myers Squibb, has agreed to provide Cipla with a licence to Celgene’s required patents. Cipla can then sell or manufacture certain volume-limited amounts of generic Lenalidomide in the United States sometime after March 2022.

United Phosphorus Limited (UPL) has denied news relating to the forensic audit initiation by SEBI in respect to the whistleblower complaint raised against the company.

The market opened in green on December 14, 2020.

The market opened in green on December 14, 2020, overall volumes in futures & options currently stand at 2,09,10,961 contracts with a turnover of Rs. 18,01,927.52 crore.

The market opened in green on December 14, 2020, overall volumes in futures & options currently stand at 2,09,10,961 contracts with a turnover of Rs. 18,01,927.52 crore.

A subsidiary of Biocon Limited i.e. Biocon Biologics and Mylan, a subsidiary of Viatris Inc., have received a positive opinion from European Medicines Agency's committee for medicinal products for human use (CHMP), recommending approval of the market authorisation of Kixelle, a biosimilar Insulin Aspart, which is rapid-acting insulin for the treatment of type 1 and 2 diabetes.

KEC International Ltd, a flagship company of RPG Enterprises, informed that it has received new orders worth Rs 1,438 crore. This order is divided into various businesses namely railways, civil, transmission & distribution as well as cables.

United States Food & Drug Administration (USFDA) has issued the first emergency use authorisation (EUA) as a vaccine for COVID-19.

UPL: UPL has denied a report appearing in certain sections of the media that SEBI has initiated a forensic audit with respect to the whistle-blower complaint. UPL is asking SEBI to inquire about this and similar malicious reporting in the last few months.

In the last week, volatility was witnessed on the Indian shores, especially in the last trading session of the week as the market swung both ways before settling the day with modest gains. The extinct bears had attempted all tricks in the books to make a comeback but all efforts were in vain as the mighty bulls were backed by the strong liquidity gush by FIIs.